cabergoline has been researched along with Local Neoplasm Recurrence in 21 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 5 (23.81) | 29.6817 |
2010's | 8 (38.10) | 24.3611 |
2020's | 8 (38.10) | 2.80 |
Authors | Studies |
---|---|
Chen, S; Dong, J; Gu, J; Jiang, X; Li, D; Wen, X; Zou, Y | 1 |
Borhan, MK; Tan, FHS | 1 |
Leshchenko, OY | 1 |
Berberoğlu, M; Bilici, E; Ceran, A; Kontbay, T; Özsu, E; Şıklar, Z; Uyanık, R | 1 |
Espinosa-Cárdenas, E; Mendoza-Zubieta, V; Mercado, M; Ramírez-Rentería, C; Sánchez-García, M; Sosa-Eroza, E | 1 |
Ahn, SS; Kim, D; Kim, EH; Kim, K; Ku, CR; Lee, EJ; Moon, JH; Park, YW | 1 |
Astafyeva, LI; Kadashev, BA; Kalinin, PL; Melnichenko, GA; Sharipov, OI; Shishkina, LV; Sidneva, JG | 1 |
Bronstein, MD; Greenman, Y | 1 |
Bilbao, I; Egaña, N; García, C; Olaizola, I | 1 |
Ikeda, H; Tominaga, T; Watanabe, K; Yoshimoto, T | 1 |
Couldwell, WT; Eloy, JA; Liu, JK; Wong, A | 1 |
Arduç, A; Berker, D; Doğan, BA; Güler, S; Işık, S; Nasıroğlu, NI; Tuna, MM | 1 |
Dogansen, SC; Selcukbiricik, OS; Tanrikulu, S; Yarman, S | 1 |
Bellaviti Buttoni, P; Carosi, G; Ferrante, E; Filopanti, M; Malchiodi, E; Mantovani, G; Profka, E; Rodari, G; Sala, E; Spada, A; Verrua, E | 1 |
Ahmad, MS; Nakhleh, A; Pearl, IW; Reut, M; Saiegh, L; Shechner, C | 1 |
Arda, N; Comlekci, A; Men, S; Yener, S; Yesil, S | 1 |
Courtney, HC; Hunter, SJ; Johnston, PC; Mc Cance, DR | 1 |
Chang, JY; Kattah, JC; Orth, EH; Talkad, AV; Xu, MY | 1 |
Werner, S | 1 |
Beckers, A; Bloch, B; Kalife, A; Petrossians, P; Ronci, N; Stevenaert, A; Tabarin, A; Valdés Socin, H | 1 |
Agostini, S; Billeci, D; Conte, N; De Menis, E; Marton, E; Tramontin, P; Visentin, A | 1 |
2 review(s) available for cabergoline and Local Neoplasm Recurrence
Article | Year |
---|---|
The recurrence of prolactinoma after withdrawal of dopamine agonist: a systematic review and meta-analysis.
Topics: Bromocriptine; Cabergoline; Deprescriptions; Dopamine Agonists; Humans; Neoplasm Recurrence, Local; Pituitary Neoplasms; Prolactinoma | 2021 |
Update on prolactinomas. Part 2: Treatment and management strategies.
Topics: Bromocriptine; Cabergoline; Disease Management; Dopamine Agonists; Drug Administration Schedule; Drug Resistance, Neoplasm; Ergolines; Female; Humans; Hyperprolactinemia; Magnetic Resonance Imaging; Neoplasm Recurrence, Local; Neuroendoscopy; Pituitary Neoplasms; Pregnancy; Pregnancy Complications, Neoplastic; Prolactin; Prolactinoma; Radiosurgery; Sphenoid Sinus | 2015 |
19 other study(ies) available for cabergoline and Local Neoplasm Recurrence
Article | Year |
---|---|
Aggressive giant prolactinoma: a case report.
Topics: Adolescent; Adult; Cabergoline; Female; Humans; Neoplasm Recurrence, Local; Pituitary Neoplasms; Prolactin; Prolactinoma; Temozolomide; Young Adult | 2022 |
[Hyperprolactinemia in the postmenopause: versions and contraversions].
Topics: Cabergoline; Dopamine Agonists; Estrogens; Female; Humans; Hyperprolactinemia; Neoplasm Recurrence, Local; Pituitary Neoplasms; Postmenopause; Progestins; Prolactin; Prolactinoma | 2021 |
Hyperprolactinemia in children and adolescents and longterm follow-up results of prolactinoma cases: a single-centre experience.
Topics: Adolescent; Cabergoline; Child; Child, Preschool; Female; Follow-Up Studies; Humans; Hyperprolactinemia; Infant; Male; Neoplasm Recurrence, Local; Pituitary Neoplasms; Prolactin; Prolactinoma; Retrospective Studies | 2022 |
High biochemical recurrence rate after withdrawal of cabergoline in prolactinomas: is it necessary to restart treatment?
Topics: Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Male; Neoplasm Recurrence, Local; Pituitary Neoplasms; Prolactin; Prolactinoma | 2020 |
Biochemical Remission after Cabergoline Withdrawal in Hyperprolactinemic Patients with Visible Remnant Pituitary Adenoma.
Topics: Adolescent; Adult; Biomarkers, Pharmacological; Biomarkers, Tumor; Cabergoline; Cohort Studies; Female; Humans; Hyperprolactinemia; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm, Residual; Pituitary Neoplasms; Prolactinoma; Remission Induction; Republic of Korea; Retrospective Studies; Treatment Outcome; Withholding Treatment; Young Adult | 2021 |
[Changes in the morphological structure of giant prolactinoma during treatment with cabergoline].
Topics: Adult; Cabergoline; Dopamine Agonists; Ergolines; Humans; Neoplasm Recurrence, Local; Pituitary Neoplasms; Prolactinoma | 2020 |
Cabergoline should be attempted in progressing non-functioning pituitary macroadenoma.
Topics: Adenoma; Cabergoline; Chemotherapy, Adjuvant; Disease Progression; Humans; Neoplasm Recurrence, Local; Neoplasm, Residual; Neurosurgical Procedures; Patient Selection; Pituitary Neoplasms; Practice Patterns, Physicians'; Tumor Burden | 2021 |
Failure of a second temozolomide cycle in a patient with a prolactin-secreting pituitary carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Bromocriptine; Cabergoline; Combined Modality Therapy; Dacarbazine; Drug Substitution; Ergolines; Fatal Outcome; Headache; Humans; Hyperprolactinemia; Liver Neoplasms; Male; Neoplasm Recurrence, Local; Pituitary Neoplasms; Prolactin; Prolactinoma; Proton Therapy; Temozolomide | 2017 |
Transsphenoidal microsurgical results of female patients with prolactinomas.
Topics: Adult; Cabergoline; Cavernous Sinus; Dopamine Agonists; Endoscopy; Ergolines; Female; Humans; Magnetic Resonance Imaging; Microsurgery; Neoplasm Recurrence, Local; Neurosurgical Procedures; Pituitary Neoplasms; Postoperative Complications; Pregnancy; Prolactin; Prolactinoma; Retrospective Studies; Sphenoid Bone; Treatment Outcome | 2013 |
Evaluation of atherosclerosis after cessation of cabergoline therapy in patients with prolactinoma.
Topics: Adolescent; Adult; Atherosclerosis; Brachial Artery; Cabergoline; Carotid Intima-Media Thickness; Cross-Sectional Studies; Ergolines; Female; Humans; Neoplasm Recurrence, Local; Pituitary Neoplasms; Prolactin; Prolactinoma; Prospective Studies; Young Adult | 2016 |
Withdrawal of dopamine agonist therapy in prolactinomas: In which patients and when?
Topics: Adolescent; Adult; Aged; Bromocriptine; Cabergoline; Deprescriptions; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Male; Middle Aged; Neoplasm Recurrence, Local; Patient Selection; Pituitary Neoplasms; Prolactin; Prolactinoma; Retrospective Studies; Time Factors; Tumor Burden; Young Adult | 2016 |
Recurrence of hyperprolactinemia following dopamine agonist withdrawal and possible predictive factors of recurrence in prolactinomas.
Topics: Adult; Aged; Biomarkers; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Male; Middle Aged; Neoplasm Recurrence, Local; Pituitary Neoplasms; Prognosis; Prolactinoma; Tomography, X-Ray Computed; Withholding Treatment | 2016 |
Cabergoline treatment for recurrent Cushing's disease during pregnancy.
Topics: Adult; Antineoplastic Agents; Biomarkers; Cabergoline; Ergolines; Female; Humans; Hydrocortisone; Live Birth; Magnetic Resonance Imaging; Neoplasm Recurrence, Local; Neoplasm, Residual; Pituitary ACTH Hypersecretion; Pregnancy; Pregnancy Complications; Remission Induction; Treatment Outcome | 2016 |
Misdiagnosis due to the hook effect in prolactin assay.
Topics: Antineoplastic Agents; Cabergoline; Diabetes Insipidus, Neurogenic; Diagnostic Errors; Ergolines; Female; Glucocorticoids; Humans; Hypopituitarism; Middle Aged; Neoplasm Recurrence, Local; Pituitary Neoplasms; Prednisolone; Prolactin; Prolactinoma; Thyroxine | 2008 |
Macroprolactinomas presenting as nasal polyps: a series of three cases.
Topics: Adult; Antineoplastic Agents; Cabergoline; Diagnosis, Differential; Diagnostic Errors; Ergolines; Humans; Male; Middle Aged; Nasal Polyps; Neoplasm Recurrence, Local; Pituitary Neoplasms; Prolactin | 2012 |
Prolactinoma presenting as painful postganglionic Horner syndrome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain; Bromocriptine; Cabergoline; Carotid Arteries; Dopamine Agonists; Ergolines; Horner Syndrome; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Migraine Disorders; Neoplasm Recurrence, Local; p-Hydroxyamphetamine; Pituitary Neoplasms; Prolactin; Prolactinoma; Remission Induction | 2004 |
[Recurrence of prolactinoma surveyed. Hormone therapy can safely be withdrawn for a long time in patients with normalized prolactin levels and invisible tumor].
Topics: Antineoplastic Agents; Cabergoline; Dopamine Agonists; Ergolines; Humans; Neoplasm Recurrence, Local; Pituitary Neoplasms; Prolactin; Prolactinoma | 2004 |
ACTH silent adenoma shrinking under cabergoline.
Topics: Adenoma; Adrenocorticotropic Hormone; Aged; Antineoplastic Agents; Autoradiography; Cabergoline; Ergolines; Humans; In Situ Hybridization; Male; Neoplasm Recurrence, Local; Pituitary Neoplasms; Prolactinoma; Receptors, Dopamine D2; RNA, Messenger | 2001 |
Pituitary adenomas in childhood and adolescence. Clinical analysis of 10 cases.
Topics: Acromegaly; Adenoma; Adolescent; Amenorrhea; Bromocriptine; Cabergoline; Child; Ergolines; Female; Headache; Human Growth Hormone; Humans; Male; Neoplasm Recurrence, Local; Octreotide; Pituitary Neoplasms; Prolactinoma; Puberty, Delayed; Radiotherapy; Treatment Outcome; Vision Disorders; Visual Fields | 2001 |